REG - Mast Energy Dvlpmts. - Broker Warrant Exercise

Mast Energy DevelopmentsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250725:nRSY4893Sa&default-theme=true

RNS Number : 4893S  Mast Energy Developments PLC  25 July 2025

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

('MED' or 'the Company')

 

Dated: 25 July 2025

 

MAST Energy Developments PLC

 

Exercise of Historic Broker Warrants, Issue of Equity & TVR

 

Mast Energy Developments PLC ("MED" or "the Company"), the UK-based
multi-asset owner, developer, and operator in the rapidly growing Flexible
Generation Power market, announces that it has received notices of exercise
for a total of 243,750 new ordinary MED shares at the exercise price of £0.08
(the "Broker Warrant Shares"). The broker warrants were historically issued to
nominees of Novum Securities Limited on 29 May 2024, the details of which are
contained in the Company's RNS announcement dated 7 May 2024. The price and
number of warrants were re-stated as part of the Company's recent share
capital consolidation and re-admission of its ordinary share capital,
effective 14 July 2025.

 

Total Voting Rights

Application will be made for the admission of the 243,750 Broker Warrant
Shares to trading on the LSE ("Admission") pursuant to the authorities
approved by shareholders at the General Meeting held on 8 July 2025. The
Shares will rank pari passu with the existing ordinary shares and it is
expected that Admission will become effective at 8.00 a.m. on 30 July 2025.

 

Following Admission, the Company's issued share capital will consist of
13,248,927 ordinary shares with voting rights. MED  does not hold any
ordinary shares in treasury. This figure of 13,248,927 may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they require to notify their interest in, or a change
to their interest in, the share capital of the Company under the UK Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Following Admission, the beneficial holding of Paul Venter, non-executive
director and chairman of the Company,  will change from 15.06% to 14.79%
interest in the issued share capital of the Company.

 

 

Stay up to date with MED's latest news and updates by joining our emailing
list and social media channels, as follows:

 

MED general enquiries - https://www.med.energy/contact
(https://www.med.energy/contact)

MED email alerts - https://www.med.energy/rnsannoucements-1
(https://www.med.energy/rnsannoucements-1)

MED LinkedIn page -
https://uk.linkedin.com/company/mast-energy-developments-plc
(https://uk.linkedin.com/company/mast-energy-developments-plc)

MED X (formerly Twitter) handle - @mastplc

ENDS

 

This announcement contains inside information for the purposes of the UK
version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ('UK MAR'). Upon the publication of this announcement, this inside
information is now considered to be in the public domain.

 

 Pieter Krügel      info@med.energy (mailto:info@med.energy)  Mast Energy           CEO

                                                              Developments PLC
 Guy Wheatley, CFA  +44 (0)74 9398 9014                       Fortified Securities  Corporate Broker
 Jon Belliss        +44 (0)20 7399 9425                       Novum Securities      Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEDFLLEISEIW